Guardant Health's Breast Cancer Diagnostic Approved by US FDA

MT Newswires Live09-08

Guardant Health's (GH) Guardant360 CDx has been approved by the US Food and Drug Administration as a companion diagnostic for advanced metastatic breast cancer, the company said Friday.

The specific indication for the diagnostic combination is to identify patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer harboring tumors with specific mutations before radiographic progression who may benefit from treatment with AstraZeneca's (AZN) Etcamah, the company said.

The approval is based on data from a clinical trial showing a 56% reduction in the risk of progression or death, the company said.

Shares of the company were up 1% in recent premarket trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2665321994?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-08 18:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2665321994","market":"fut","top_or_hot":-1,"title":"Guardant Health's Breast Cancer Diagnostic Approved by US FDA","media":"MT Newswires Live","content":"<html><body><p> Guardant Health's (GH) Guardant360 CDx has been approved by the US Food and Drug Administration as a companion diagnostic for advanced metastatic breast cancer, the company said Friday.</p><p>The specific indication for the diagnostic combination is to identify patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer harboring tumors with specific mutations before radiographic progression who may benefit from treatment with AstraZeneca's (AZN) Etcamah, the company said.</p><p>The approval is based on data from a clinical trial showing a 56% reduction in the risk of progression or death, the company said.</p><p>Shares of the company were up 1% in recent premarket trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Guardant Health's Breast Cancer Diagnostic Approved by US FDA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGuardant Health's Breast Cancer Diagnostic Approved by US FDA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-08 18:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Guardant Health's (GH) Guardant360 CDx has been approved by the US Food and Drug Administration as a companion diagnostic for advanced metastatic breast cancer, the company said Friday.</p><p>The specific indication for the diagnostic combination is to identify patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer harboring tumors with specific mutations before radiographic progression who may benefit from treatment with AstraZeneca's (AZN) Etcamah, the company said.</p><p>The approval is based on data from a clinical trial showing a 56% reduction in the risk of progression or death, the company said.</p><p>Shares of the company were up 1% in recent premarket trading.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FFOX","symbol_name":"FUNDX FUTURE FUND OPPORTUNITIES ETF","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2665321994","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2665321994","pubTimestamp":1788862114,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Guardant Health's  Guardant360 CDx has been approved by the US Food and Drug Administration as a companion diagnostic for advanced metastatic breast cancer, the company said Friday.The specific indication for the diagnostic combination is to identify patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer harboring tumors with specific mutations before radiographic progression who may benefit from treatment with AstraZeneca's  Etcamah, the company said.The approval is based on data from a clinical trial showing a 56% reduction in the risk of progression or death, the company said.Shares of the company were up 1% in recent premarket trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FFOX":"FUNDX FUTURE FUND OPPORTUNITIES ETF","GH":"Guardant Health Inc.","LU0058720904.USD":"联博国际健康护理基金A","BK4007":"制药","BK4551":"寇图资本持仓","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","AZNH":"ASTRAZENECA PLC ADRhedged","BK4196":"保健护理服务","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","GDOC":"Goldman Sachs Future Health Care Equity ETF","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","GNMX":"Corgi Genomics & Precision Medicine ETF","EKG":"First Trust Nasdaq Lux Digital Health Solutions ETF","BK4585":"ETF&股票定投概念","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","GNOM":"Global X Genomics & Biotechnology ETF","LFSC":"F/m Emerald Life Sciences Innovation ETF","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","AZN":"阿斯利康","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","BK4535":"淡马锡持仓","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","PTH":"Invesco Dorsey Wright Healthcare Momentum ETF","LABU":"三倍做多标普生物-Direxion","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","HELX":"Franklin Genomic Advancements ETF","BK4568":"美国抗疫概念","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","BK4588":"碎股","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC"},"translate_title":"Guardant Health的乳腺癌诊断获得美国FDA批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1,"AZNH":0.6,"HELX":0.6,"GNOM":0.6,"FFOX":0.6,"EKG":0.6,"LABU":1.5,"LFSC":0.6,"GH":1,"GNMX":0.6,"PTH":0.6,"GDOC":0.6},"content_text":"Guardant Health's (GH) Guardant360 CDx has been approved by the US Food and Drug Administration as a companion diagnostic for advanced metastatic breast cancer, the company said Friday.The specific indication for the diagnostic combination is to identify patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer harboring tumors with specific mutations before radiographic progression who may benefit from treatment with AstraZeneca's (AZN) Etcamah, the company said.The approval is based on data from a clinical trial showing a 56% reduction in the risk of progression or death, the company said.Shares of the company were up 1% in recent premarket trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2665321994","isCrawlerRequest":true}